Roth Capital Resumes Coverage on RXi Pharmaceuticals (RXII) at Buy
Tweet
Share
E-mailGet Alerts RXII Hot Sheet
Price: $0.33 --0%
Rating Summary:
3 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 15 | New: 50
Rating Summary:
3 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 15 | New: 50
Join SI Premium – FREE
Roth Capital resumes coverage on RXi Pharmaceuticals (NASDAQ: RXII) with a Buy. PT $5.
For more ratings news on RXi Pharmaceuticals click here and for the rating history of RXi Pharmaceuticals click here.
Shares of RXi Pharmaceuticals closed at $1.30 yesterday.
For more ratings news on RXi Pharmaceuticals click here and for the rating history of RXi Pharmaceuticals click here.
Shares of RXi Pharmaceuticals closed at $1.30 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Lucid Capital Markets Starts Service Properties Trust (SVC) at Buy
- RBC Capital Assumes Pentair (PNR) at Sector Perform
- Huntington Starts Innovative Industrial Properties (IIPR) at Outperform
Create E-mail Alert Related Categories
New CoverageRelated Entities
Roth CapitalSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
